{"id":12690,"date":"2024-10-11T17:21:00","date_gmt":"2024-10-11T15:21:00","guid":{"rendered":"https:\/\/valintermed.com\/?p=12690"},"modified":"2024-10-11T17:21:00","modified_gmt":"2024-10-11T15:21:00","slug":"sindrom-opuholi-gamartomy-pten","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/tumour-gamartomy-syndrome\/","title":{"rendered":"PTEN hamartoma tumor syndrome"},"content":{"rendered":"<div class=\"fpm_start\"><\/div>\n<p>PTEN hamartoma tumor syndrome (PH-PTEN) is a hereditary disorder that belongs to a group of syndromes associated with a predisposition to tumor formation. This condition is associated with abnormalities in the PTEN gene, which plays a key role in the regulation of cell growth and apoptosis. The main manifestations of the syndrome are the formation of hamartomas - benign tumors affecting various organs and systems. Patients with PH-PTEN are at high risk of developing various malignancies, including breast, thyroid, and endometrial cancer. In addition, the syndrome may be accompanied by neurological disorders, skin manifestations, and multiple other systemic disorders.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-flat ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Content<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 eztoc-toggle-hide-by-default' ><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tumour-gamartomy-syndrome\/#%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\" >History of the disease and interesting historical facts<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tumour-gamartomy-syndrome\/#%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F\" >Epidemiology<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tumour-gamartomy-syndrome\/#%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E\" >Genetic predisposition to this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tumour-gamartomy-syndrome\/#%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Risk factors for the development of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tumour-gamartomy-syndrome\/#%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Diagnosis of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tumour-gamartomy-syndrome\/#%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\" >Treatment<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tumour-gamartomy-syndrome\/#%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >List of medications used to treat this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tumour-gamartomy-syndrome\/#%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Disease monitoring<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tumour-gamartomy-syndrome\/#%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Age-related features of the disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tumour-gamartomy-syndrome\/#%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\" >Questions and Answers<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\"><\/span>History of the disease and interesting historical facts<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>PTEN hamartoma tumor syndrome was first described in the early 1990s, when scientists began to associate mutations in the PTEN gene with the development of certain types of tumors. As clinical and molecular data accumulated, characteristic manifestations of the syndrome were established, which made it possible to isolate it as a separate nosological entity. Population studies played an important role in the study of the disease, confirming the role of PTEN as a tumor suppressor, which became the basis for a deeper understanding of the molecular mechanisms underlying SOH-PTEN. Interestingly, the vast majority of known cases are associated with autosomal dominant inheritance, which indicates a high risk of transmitting the disease to offspring.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F\"><\/span>Epidemiology<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Current data suggest that the incidence varies, but the general prevalence is approximately 1 in 100,000 in the population. However, the actual incidence may be higher due to under-detection of mild forms of the disease and lack of genetic testing. In some populations, particularly those with known predisposition to cancer, the incidence may be as high as 1 in 10,000. It is important to note that the efficiency of clinical detection of individual cases or clusters in the general population may have affected the epidemiological data needed to reliably understand the true burden of the syndrome in the population.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E\"><\/span>Genetic predisposition to this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The genetic basis of PTEN hamartoma tumor syndrome is a mutation in the PTEN gene located on chromosome 10 (10q23.31). More than 70% patients with SOH-PTEN have various types of mutations, including point mutations, deletions, and insertions that lead to dysfunction of this gene. PTEN encodes a phosphatase whose efficiency is reduced in the presence of mutations, which disrupts signaling associated with insulin and cell growth. Importantly, mutations in other important genes such as AKT1 and PIK3CA may also be detected in individual patients, confirming the multifaceted molecular mechanics of the position of the syndrome in the pathological process.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Risk factors for the development of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>There are several factors that increase the likelihood of developing PTEN hamartoma tumor syndrome, including:<\/p>\n<ul>\n<li>Heredity: presence of sick relatives in the first degree of kinship.<\/li>\n<li>Problems in the genetic testing system: the lack of genetic testing of relatives increases the likelihood of missing cases.<\/li>\n<li>Ethnic groups: Some populations have an increased risk due to their gene pool and living conditions.<\/li>\n<\/ul>\n<p>We must not forget about social and economic factors that may affect the availability of early diagnosis and genetic testing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Diagnosis of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Diagnosis of PTEN hamartoma tumor syndrome involves a comprehensive approach that takes into account:<\/p>\n<ul>\n<li>Main symptoms: skin manifestations (hair loss, skin changes), formation of tumors in various organs.<\/li>\n<li>Laboratory tests: genetic analysis for mutations in the PTEN gene.<\/li>\n<li>Radiological examinations: ultrasound, MRI and CT to detect tumors and hamartomas in organs.<\/li>\n<li>Other types of diagnostics: biopsy for morphological examination of formations.<\/li>\n<li>Differential diagnosis: It is necessary to exclude other tumor-associated syndromes, such as Li-Fraumeni syndrome and Bates syndrome.<\/li>\n<\/ul>\n<p>This approach allows us to establish a diagnosis and begin treatment with high accuracy.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\"><\/span>Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Treatment of PTEN hamartoma tumor syndrome requires a multidisciplinary approach, including:<\/p><script data-noptimize=\"\" data-wpfc-render=\"false\">\nfpm_start( \"true\" );\n<\/script>\n\n<ul>\n<li>General treatment: regular observation and monitoring of the patient&#039;s condition.<\/li>\n<li>Pharmacological treatment: use of mammalian target of rapamycin (mTOR) inhibitors to reduce the risk of tumor progression.<\/li>\n<li>Surgical treatment: resection of benign tumors if they cause clinical symptoms or have fractions susceptible to malignancy.<\/li>\n<li>Other treatments: Genetic counseling to inform patients about risks to offspring.<\/li>\n<\/ul>\n<p>Treatment tactics are selected individually depending on the manifestations of the disease and the degree of risk.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>List of medications used to treat this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Today, the following groups of drugs are distinguished:<\/p>\n<ul>\n<li>mTOR inhibitors (eg, Everolimus).<\/li>\n<li>Systemic chemotherapy drugs for malignant tumors (eg, Doxorubicin, Paclitaxel).<\/li>\n<li>Drugs aimed at symptomatic treatment (for example, painkillers, antifungals).<\/li>\n<\/ul>\n<p>Chemotherapy is used in cases of malignant tumors and requires careful monitoring due to possible complications.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Disease monitoring<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Monitoring of the patient&#039;s condition includes:<\/p>\n<ul>\n<li>Regular monitoring by a genetic counselor and oncologist.<\/li>\n<li>Follow-up examinations every 6-12 months for early detection of possible tumors.<\/li>\n<li>Systematic assessment of the patient&#039;s quality of life and social functioning.<\/li>\n<\/ul>\n<p>Prognosis depends on the severity of symptoms, the presence of malignancy, and the overall response to therapeutic strategies used. Complications may include tumor progression, surgical risk, and difficulties in drug therapy.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Age-related features of the disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>PTEN hamartoma tumor syndrome manifests itself differently depending on the age group of patients:<\/p>\n<ul>\n<li>Childhood: May present with obvious skin lesions and swelling, but in most cases does not cause serious complications.<\/li>\n<li>Adolescence and young adulthood: frequent occurrence of somatic diseases and increased risk of developing malignant tumors such as breast cancer.<\/li>\n<li>Adulthood: Risk increases with age, especially in postmenopausal women.<\/li>\n<\/ul>\n<p>This approach allows us to take into account the dynamics of the disease at various stages of the patient\u2019s life.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\"><\/span>Questions and Answers<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>What are the main symptoms of PTEN hamartoma tumor syndrome?<\/strong> The main symptoms include skin changes such as lichen and the formation of benign tumors, as well as systemic manifestations in the form of breast, thyroid and endometrial cancer.<\/li>\n<li><strong>How can PTEN hamartoma tumor syndrome be diagnosed?<\/strong> Diagnosis is based on clinical data, genetic testing, and radiological studies to detect tumor formations.<\/li>\n<li><strong>What are the chances of developing malignant tumors in patients with this syndrome?<\/strong> The chances of developing malignant tumors increase significantly, especially for breast and endometrial cancer \u2013 up to 85% at the age of over 40 years.<\/li>\n<li><strong>What treatment is recommended for PTEN hamartoma tumor syndrome?<\/strong> Treatment includes general observation, pharmacological blockade of mTOR, and surgical resection of lesions when necessary.<\/li>\n<li><strong>How often should follow-up examinations be performed?<\/strong> Follow-up examinations are recommended every 6-12 months depending on individual manifestations and the presence of malignant tumors.<\/li>\n<\/ul>\n<div class=\"fpm_end\"><\/div>","protected":false},"excerpt":{"rendered":"<p>PTEN hamartoma tumor syndrome (PTEN-HTS) is an inherited disorder that belongs to a group of syndromes associated with a predisposition to tumor formation. This condition<\/p>","protected":false},"author":1,"featured_media":22337,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[298],"tags":[],"class_list":["post-12690","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medlibrary"],"_links":{"self":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/12690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/comments?post=12690"}],"version-history":[{"count":1,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/12690\/revisions"}],"predecessor-version":[{"id":14389,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/12690\/revisions\/14389"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media\/22337"}],"wp:attachment":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media?parent=12690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/categories?post=12690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/tags?post=12690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}